TEADs were altered about 14% (67 samples out of 478 samples) in patients with stomach adenocarcinoma, and the proportion of amplification in genetic alterations was 30% for TEAD3 and 36% for TEAD4 (Fig. 3A). Here, TEAD4 is linked to gastric adenocarcinoma.